bioRxivBioengineeringPreprint
Evolutionary algorithms accelerate de novo design of potent Nectin-4-specific cancer biologics
Elisabeth TaniD, Sophie C Frechen, Bianca BroskeiD, Julia M. MessmeriD, Tim Noah KempcheniD, Benjamin A. McEnroeiD, Dominic FerberiD, Leonie Waluga, Eduard BelowiD, Alexander HochiD, Michelle C.R. YongiD, Johannes OldenburgiD, Heiko RühliD, Matthias GeyeriD, Marieta Ioana TomaiD, Niklas KlümperiD, Tobias BaldiD, Jonathan Leo Schmid-BurgkiD, Michael HölzeliD, Gregor HageluekeniD
Abstract
Recent advances in AI-based structural biology have made de novo protein binder design increasingly effective, yet performance remains highly target dependent. For instance, the cancer surface antigen Nectin-4, an immunoglobulin-like cell adhesion protein, proved particularly challenging for RFdiffusion-based minibinder generation, yielding substantially fewer high-quality candidates than related targets. To address this bottleneck, we integrated an evolutionary genetic algorithm (GA) with AI-driven design. GA selection with tunable stringency was coupled with diversification via partial diffusion or direct sequence editing, enabling efficient exploration of sequence-structure space and rapid enrichment of promising candidates. This AI-GA pipeline quickly produced large and diverse minibinder panels with very good in silico quality metrics and is compatible with inputs from multiple design algorithms. Pooled, large-scale experimental screening identified highly stable Nectin-4 minibinders with single-digit nanomolar down to subnanomolar affinities. Lead binders were further engineered into Nectin-4-specific flow cytometry detection reagents and potent bispecific T cell engagers, demonstrating functional activity beyond binding. Together, these results show that evolutionary refinement can unlock challenging targets and accelerate de novo protein design for next-generation cancer biologics.
- organism: human
- assay: protein structure
- research focus: drug response / drug discovery
- approach: deep learning
- approach: genetic perturbation / CRISPR
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Development of AI-designed protein binders for detection and targeting of cancer cell surface proteins
Bianca Broske, Sophie C. Binder, … Michael Hölzel·bioRxiv·May 11, 2025
- Sequence and structural determinants of efficacious de novo chimeric antigen receptors
Arthur Chow, Hoyin Chu, … Caleb A. Lareau·bioRxiv·Dec 13, 2025
- Engineering de novo binder CAR-T cell therapies with generative AI
Markus Mergen, Daniela Abele, … Andrea Schmidts·bioRxiv·Nov 25, 2024
- Validation and analysis of 12,000 AI-driven CAR-T designs in the Bits to Binders competition
Clayton W. Kosonocky, Alex M. Abel, … Rohit Satija·Molecular Systems BiologyPeer-reviewed·Oct 8, 2026
- Precision at Every Scale: Efficiency in AI-Driven De Novo Antibody Design
Hyeonjin Cha, Kyesoo Cho, … Jinsol Yang·bioRxiv·Nov 21, 2025
- BindCraft: one-shot design of functional protein binders
Martin Pačesa, Lennart Nickel, … Bruno E. Correia·bioRxiv·Sep 30, 2024